Tenaya Therapeutics’ TN-201, designed to target MYBPC3 in hypertrophic cardiomyopathy, has demonstrated successful vector delivery and transgene expression in cardiac tissue [152]. The gene discussed is MYBPC3; the disease is hypertrophic cardiomyopathy.